Reversible autonomic dysfunction during antiviral treatment in patients with chronic hepatitis C virus infection

J. Osztovits, Evelin Horváth, Judit Tax, Levente Csihi, Tamás Horváth, Levente Littvay, T. Tóth, Margit Abonyi, P. Lakatos, M. Kollai, J. Fehér, F. Szalay, Hubert E. Blum

Research output: Article

3 Citations (Scopus)

Abstract

Background: The first clinical sign of chronic hepatitis C virus (HCV) infection can be one of the various extrahepatic manifestations. During antiviral treatment, symptoms of HCV-associated neuropathies usually improve, but can also worsen and lead to discontinuation of anti-HCV therapy. Recently, we have reported autonomic dysfunction in patients with HCV infection. Objectives: In the present prospective study, we analyzed the changes of autonomic function during anti-HCV treatment. Patients and Methods: Cardiovagal autonomic function was assessed in 22 HCV RNA-positive, treatment-naive patients by determining heart rate variability (HRV) and baroreflex sensitivity (BRS), at the beginning of treatment and 12, 24 and 48 weeks of antiviral therapy. interferon alfa-2 and ribavirin were given according to the guidelines. Results: Both HRV and BRS time and frequency domain indices decreased after 12 weeks of therapy compared to the pre-treatment values; then the mean±SD values increased significantly by week 24 and continued to improve by week 48 of therapy-253.0±156.1 ms before therapy vs 111.6±81.9 at week 12, and 183.4±169.6 at week 24 vs 211.6±149.1 ms at week 48 for low-frequency HRV index; p

Original languageEnglish
Pages (from-to)114-118
Number of pages5
JournalHepatitis Monthly
Volume11
Issue number2
Publication statusPublished - febr. 2011

Fingerprint

Chronic Hepatitis C
Virus Diseases
Hepacivirus
Antiviral Agents
Therapeutics
Baroreflex
Heart Rate
Ribavirin
Interferon-alpha
Prospective Studies
Guidelines
RNA

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases

Cite this

Osztovits, J., Horváth, E., Tax, J., Csihi, L., Horváth, T., Littvay, L., ... Blum, H. E. (2011). Reversible autonomic dysfunction during antiviral treatment in patients with chronic hepatitis C virus infection. Hepatitis Monthly, 11(2), 114-118.

Reversible autonomic dysfunction during antiviral treatment in patients with chronic hepatitis C virus infection. / Osztovits, J.; Horváth, Evelin; Tax, Judit; Csihi, Levente; Horváth, Tamás; Littvay, Levente; Tóth, T.; Abonyi, Margit; Lakatos, P.; Kollai, M.; Fehér, J.; Szalay, F.; Blum, Hubert E.

In: Hepatitis Monthly, Vol. 11, No. 2, 02.2011, p. 114-118.

Research output: Article

Osztovits, J. ; Horváth, Evelin ; Tax, Judit ; Csihi, Levente ; Horváth, Tamás ; Littvay, Levente ; Tóth, T. ; Abonyi, Margit ; Lakatos, P. ; Kollai, M. ; Fehér, J. ; Szalay, F. ; Blum, Hubert E. / Reversible autonomic dysfunction during antiviral treatment in patients with chronic hepatitis C virus infection. In: Hepatitis Monthly. 2011 ; Vol. 11, No. 2. pp. 114-118.
@article{0598c041de864d0a87435c98cc02d106,
title = "Reversible autonomic dysfunction during antiviral treatment in patients with chronic hepatitis C virus infection",
abstract = "Background: The first clinical sign of chronic hepatitis C virus (HCV) infection can be one of the various extrahepatic manifestations. During antiviral treatment, symptoms of HCV-associated neuropathies usually improve, but can also worsen and lead to discontinuation of anti-HCV therapy. Recently, we have reported autonomic dysfunction in patients with HCV infection. Objectives: In the present prospective study, we analyzed the changes of autonomic function during anti-HCV treatment. Patients and Methods: Cardiovagal autonomic function was assessed in 22 HCV RNA-positive, treatment-naive patients by determining heart rate variability (HRV) and baroreflex sensitivity (BRS), at the beginning of treatment and 12, 24 and 48 weeks of antiviral therapy. interferon alfa-2 and ribavirin were given according to the guidelines. Results: Both HRV and BRS time and frequency domain indices decreased after 12 weeks of therapy compared to the pre-treatment values; then the mean±SD values increased significantly by week 24 and continued to improve by week 48 of therapy-253.0±156.1 ms before therapy vs 111.6±81.9 at week 12, and 183.4±169.6 at week 24 vs 211.6±149.1 ms at week 48 for low-frequency HRV index; p",
keywords = "Antiviral treatment, Autonomic dysfunction, Hepatitis C virus",
author = "J. Osztovits and Evelin Horv{\'a}th and Judit Tax and Levente Csihi and Tam{\'a}s Horv{\'a}th and Levente Littvay and T. T{\'o}th and Margit Abonyi and P. Lakatos and M. Kollai and J. Feh{\'e}r and F. Szalay and Blum, {Hubert E.}",
year = "2011",
month = "2",
language = "English",
volume = "11",
pages = "114--118",
journal = "Hepatitis Monthly",
issn = "1735-143X",
publisher = "Kowsar Publishing Company",
number = "2",

}

TY - JOUR

T1 - Reversible autonomic dysfunction during antiviral treatment in patients with chronic hepatitis C virus infection

AU - Osztovits, J.

AU - Horváth, Evelin

AU - Tax, Judit

AU - Csihi, Levente

AU - Horváth, Tamás

AU - Littvay, Levente

AU - Tóth, T.

AU - Abonyi, Margit

AU - Lakatos, P.

AU - Kollai, M.

AU - Fehér, J.

AU - Szalay, F.

AU - Blum, Hubert E.

PY - 2011/2

Y1 - 2011/2

N2 - Background: The first clinical sign of chronic hepatitis C virus (HCV) infection can be one of the various extrahepatic manifestations. During antiviral treatment, symptoms of HCV-associated neuropathies usually improve, but can also worsen and lead to discontinuation of anti-HCV therapy. Recently, we have reported autonomic dysfunction in patients with HCV infection. Objectives: In the present prospective study, we analyzed the changes of autonomic function during anti-HCV treatment. Patients and Methods: Cardiovagal autonomic function was assessed in 22 HCV RNA-positive, treatment-naive patients by determining heart rate variability (HRV) and baroreflex sensitivity (BRS), at the beginning of treatment and 12, 24 and 48 weeks of antiviral therapy. interferon alfa-2 and ribavirin were given according to the guidelines. Results: Both HRV and BRS time and frequency domain indices decreased after 12 weeks of therapy compared to the pre-treatment values; then the mean±SD values increased significantly by week 24 and continued to improve by week 48 of therapy-253.0±156.1 ms before therapy vs 111.6±81.9 at week 12, and 183.4±169.6 at week 24 vs 211.6±149.1 ms at week 48 for low-frequency HRV index; p

AB - Background: The first clinical sign of chronic hepatitis C virus (HCV) infection can be one of the various extrahepatic manifestations. During antiviral treatment, symptoms of HCV-associated neuropathies usually improve, but can also worsen and lead to discontinuation of anti-HCV therapy. Recently, we have reported autonomic dysfunction in patients with HCV infection. Objectives: In the present prospective study, we analyzed the changes of autonomic function during anti-HCV treatment. Patients and Methods: Cardiovagal autonomic function was assessed in 22 HCV RNA-positive, treatment-naive patients by determining heart rate variability (HRV) and baroreflex sensitivity (BRS), at the beginning of treatment and 12, 24 and 48 weeks of antiviral therapy. interferon alfa-2 and ribavirin were given according to the guidelines. Results: Both HRV and BRS time and frequency domain indices decreased after 12 weeks of therapy compared to the pre-treatment values; then the mean±SD values increased significantly by week 24 and continued to improve by week 48 of therapy-253.0±156.1 ms before therapy vs 111.6±81.9 at week 12, and 183.4±169.6 at week 24 vs 211.6±149.1 ms at week 48 for low-frequency HRV index; p

KW - Antiviral treatment

KW - Autonomic dysfunction

KW - Hepatitis C virus

UR - http://www.scopus.com/inward/record.url?scp=79952457354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952457354&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:79952457354

VL - 11

SP - 114

EP - 118

JO - Hepatitis Monthly

JF - Hepatitis Monthly

SN - 1735-143X

IS - 2

ER -